Loading…
Based on limited metadata, this warning letter issued to Tailor Made Compounding LLC on April 1, 2020, concerns a pharmaceutical compounding operation's manufacturing practices for drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined; however, FDA warning letters to compounders typically address deficiencies in quality control, sterility assurance, or current good manufacturing practice (CGMP) compliance. The FDA's issuance of this letter indicates the agency identified serious regulatory concerns warranting formal notification to the company.